Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.

Foundayo (orforglipron) - Eli Lilly

http://www.ncbi.nlm.nih.gov/pubmed/42750540

Ambrish Singh; Florian Kahles; Hong Liu-Seifert; Jens Aberle; Jeremie Lebrec; Neena A Xavier; Runjia Li; Ryan Griffin; Shraddha Shinde; Simona Vasileva-Metodiev; Suzanne R Klise

Sep 18, 2026